Abbisko Therapeutics Co, Ltd

This phase I trial tests an experimental oral drug called ABSK211 in people with advanced solid tumors that have a KRAS gene alteration. The study aims to find a safe dose and see how well the drug works. Participants take ABSK211 by mouth once daily in 21-day cycles.

This phase 2 trial tests whether adding an experimental drug called ABSK043 to the standard targeted therapy osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, PD-L1 positive). The study enrolls adults whose cancer has spread or cannot be surg…

This study tests a new drug called ABSK061 in children aged 3 to 12 with achondroplasia, a common form of dwarfism. The drug is taken once daily and aims to improve growth rate. The trial will first find a safe dose, then check how well it works over a year. About 110 children wi…